Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Should You Buy Precision BioSciences (DTIL) After Golden Cross?
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026
Cullinan Therapeutics (NASDAQ:CGEM) versus Precision BioSciences (NASDAQ:DTIL) Critical Analysis
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision Biosciences: Still Swinging And Finally Drawing Blood
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
DTIL Revenue Drops 99%
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates